US Bancorp
NKTR icon

US Bancorp’s Nektar Therapeutics NKTR Stock Holding History

US Bancorp’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$138K Buy
1,916
+656
+52% +$37.4K ﹤0.01% 2205
2025
Q4 		$53.3K Sell
1,260
-550
-30% -$30.8K ﹤0.01% 2667
2025
Q3 		$103K Sell
1,810
-1,891
-51% -$62.6K ﹤0.01% 2334
2025
Q2 		$95.6K Buy
3,701
+362
+11% +$4.06K ﹤0.01% 2445
2025
Q1 		$34.1K Buy
3,339
+2,406
+258% +$31.4K ﹤0.01% 2931
2024
Q4 		$13K Sell
933
-200
-18% -$3.53K ﹤0.01% 3319
2024
Q3 		$22.1K Hold
1,133
– – ﹤0.01% 3085
2024
Q2 		$21.1K Buy
+1,133
New +$23.9K ﹤0.01% 3048
2023
Q4 		– Sell
-3,397
Closed -$30.3K – 4092
2023
Q3 		$30.3K Hold
3,397
– – ﹤0.01% 2679
2023
Q2 		$29.3K Sell
3,397
-577
-15% -$6.15K ﹤0.01% 2777
2023
Q1 		$41.9K Sell
3,974
-149
-4% -$4.51K ﹤0.01% 2610
2022
Q4 		$140K Sell
4,123
-342
-8% -$16.6K ﹤0.01% 2056
2022
Q3 		$215K Sell
4,465
-168
-4% -$9.99K ﹤0.01% 1807
2022
Q2 		$264K Sell
4,633
-10,956
-70% -$691K ﹤0.01% 1751
2022
Q1 		$1.26M Buy
15,589
+108
+0.7% +$16K ﹤0.01% 1077
2021
Q4 		$3.14M Sell
15,481
-1,010
-6% -$219K ﹤0.01% 745
2021
Q3 		$4.44M Sell
16,491
-1,527
-8% -$367K 0.01% 594
2021
Q2 		$4.64M Buy
18,018
+65
+0.4% +$18K 0.01% 583
2021
Q1 		$5.39M Sell
17,953
-382
-2% -$119K 0.01% 536
2020
Q4 		$4.68M Buy
18,335
+5,728
+45% +$1.48M 0.01% 556
2020
Q3 		$3.14M Buy
12,607
+6,742
+115% +$2.12M 0.01% 606
2020
Q2 		$2.04M Sell
5,865
-10
-0.2% -$3.12K 0.01% 714
2020
Q1 		$1.57M Buy
5,875
+34
+0.6% +$10.5K ﹤0.01% 750
2019
Q4 		$1.89M Sell
5,841
-6
-0.1% -$1.74K ﹤0.01% 803
2019
Q3 		$1.6M Sell
5,847
-5
-0.1% -$1.83K ﹤0.01% 839
2019
Q2 		$3.12M Buy
5,852
+39
+0.7% +$19.6K 0.01% 635
2019
Q1 		$2.93M Buy
5,813
+2
+0% +$1.19K 0.01% 638
2018
Q4 		$2.87M Hold
5,811
– – 0.01% 612
2018
Q3 		$5.31M Sell
5,811
-2
-0% -$1.71K 0.02% 492
2018
Q2 		$4.26M Sell
5,813
-10
-0.2% -$11.5K 0.01% 545
2018
Q1 		$9.28M Hold
5,823
– – 0.03% 365
2017
Q4 		$5.22M Sell
5,823
-400
-6% -$237K 0.02% 494
2017
Q3 		$2.24M Hold
6,223
– – 0.01% 748
2017
Q2 		$1.82M Hold
6,223
– – 0.01% 802
2017
Q1 		$2.19M Hold
6,223
– – 0.01% 744
2016
Q4 		$1.15M Sell
6,223
-44
-0.7% -$8.95K ﹤0.01% 996
2016
Q3 		$1.61M Buy
6,267
+44
+0.7% +$11.3K 0.01% 812
2016
Q2 		$1.33M Hold
6,223
– – 0.01% 870
2016
Q1 		$1.28M Hold
6,223
– – 0.01% 858
2015
Q4 		$1.57M Sell
6,223
-144
-2% -$29.6K 0.01% 777
2015
Q3 		$1.05M Buy
6,367
+23
+0.4% +$4.07K ﹤0.01% 937
2015
Q2 		$1.19M Hold
6,344
– – ﹤0.01% 934
2015
Q1 		$1.05M Buy
6,344
+144
+2% +$29.6K ﹤0.01% 993
2014
Q4 		$1.44M Sell
6,200
-382
-6% -$81.6K 0.01% 835
2014
Q3 		$1.19M Sell
6,582
-154
-2% -$29.5K ﹤0.01% 912
2014
Q2 		$1.29M Buy
6,736
+2,355
+54% +$416K 0.01% 879
2014
Q1 		$796K Buy
4,381
+232
+6% +$45.9K ﹤0.01% 1074
2013
Q4 		$706K Buy
4,149
+1,132
+38% +$183K ﹤0.01% 1114
2013
Q3 		$473K Buy
3,017
+2,350
+352% +$434K ﹤0.01% 1271
2013
Q2 		$116K Buy
+667
New +$102K ﹤0.01% 1944

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

US Bancorp's NKTR Position: Q1 2026 in Review

US Bancorp increased its Nektar Therapeutics (NKTR) stake by 52% in Q1 2026, buying an estimated $37.4K and bringing the position to 1,916 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #2205.

US Bancorp first reported a position in NKTR in Q2 2013 and has held it in 50 quarters since. The position peaked at $9.28M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • US Bancorp held 1,916 shares of Nektar Therapeutics worth $138K as of Q1 2026.
  • US Bancorp bought 656 Nektar Therapeutics shares in Q1 2026, an estimated $37.4K.
  • Nektar Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #2205 holding.
  • US Bancorp first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 50 quarters since.
  • US Bancorp's Nektar Therapeutics position peaked at $9.28M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.